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Background: Expression and purification of correctly folded proteins typically require screening of different
parameters such as protein variants, solubility enhancing tags or expression hosts. Parallel vector series that cover
all variations are available, but not without compromise. We have established a fast, efficient and absolutely
background free cloning approach that can be applied to any selected vector.
Results: Here we describe a method to tailor selected expression vectors for parallel Sequence and Ligation
Independent Cloning. SLIC cloning enables precise and sequence independent engineering and is based on joining
vector and insert with 15–25 bp homologies on both DNA ends by homologous recombination. We modified
expression vectors based on pET, pFastBac and pTT backbones for parallel PCR-based cloning and screening in E.coli,
insect cells and HEK293E cells, respectively. We introduced the toxic ccdB gene under control of a strong constitutive
promoter for counterselection of insert less vector. In contrast to DpnI treatment commonly used to reduce vector
background, ccdB used in our vector series is 100% efficient in killing parental vector carrying cells and reduces vector
background to zero. In addition, the 3’ end of ccdB functions as a primer binding site common to all vectors. The
second shared primer binding site is provided by a HRV 3C protease cleavage site located downstream of purification
and solubility enhancing tags for tag removal. We have so far generated more than 30 different parallel expression
vectors, and successfully cloned and expressed more than 250 genes with this vector series. There is no size restriction
for gene insertion, clone efficiency is > 95% with clone numbers up to 200. The procedure is simple, fast, efficient and
cost-effective. All expression vectors showed efficient expression of eGFP and different target proteins requested to be
produced and purified at our Core Facility services.
Conclusion: This new expression vector series allows efficient and cost-effective parallel cloning and thus screening of
different protein constructs, tags and expression hosts.
Keywords: Parallel cloning, Restriction enzyme free cloning, Expression screening, Bacterial expression, Insect cell
expression, Mammalian expression, Protein productionBackground
As central Core Facility Labs at the Max-Planck Institute of
Biochemistry and the EMBL we provide in-house services
for recombinant protein production. The proteins we are
asked to produce are from various sources and protein
families and are used for crystallization, immunization, bio-
chemical, biophysical or biological studies. We perfom in-
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reproduction in any medium, provided the orproperly folded. However, in many cases, this is a fairly
challenging task to achieve, despite the many options
that can improve proper protein folding such as con-
struct design, solubility enhancing fusion tags, expres-
sion conditions, expression hosts and improved protein
purification protocols. The constant challenge is to iden-
tify a successful combination of parameters with a mini-
mum of resources. Apart from unbiased HTP approaches
[1] or targeted selection [2,3], it still remains a time con-
suming trial and error process in most non-automated
protein labs. We had initially focused our screening efforts
on constructs and solubility tags in E. coli as a first choice.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and








































Figure 1 Principle of parallel SLIC cloning with negative ccdB
selection. The vector is PCR linearized with LP1 forward and LP2
reverse primer. The LP1 primer corresponds to PreScission protease site
(3C) for tag removal. The LP2 primer is either located at the C-terminus
of ccdB or corresponds to a C-terminal tag. In both cases the ccdB
gene is deleted upon PCR amplification thereby allowing
counterselection of parental empty vector in ccdB sensitive cells.
The Gene of Interest (GOI) is PCR amplified with primers
composed of 5’ and 3’ gene specific sequences plus 15 bp – 25 bp
extensions complementary to LP1 and LP2 vector
primers, respectively.
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or previous experience, or in case E. coli screening had
failed. As this happened frequently we decided to imple-
ment parallel testing of constructs, solubility tags and
expression hosts altogether. In order to handle all these
different expression constructs, an efficient parallel clon-
ing method was required. In the past few years, a number
of powerful combinatorial cloning methods have been
introduced. Gateway technology (Life Technologies) opened
the area of combinatorial cloning more than a decade ago.
More recent additions to the list are type II restriction
enzymes (Stargate, IBA, Germany), Golden Gate Shuffling
[4], RF cloning [5] and Sequence and Ligation Independent
Cloning SLIC [6]. For recombinant protein expression,
several commercial (Novagen, IBA, Life Technologies)
and non-commercial [7] parallel vector series are
available. However, we had already established differ-
ent expression systems with their respective vectors:
The E.coli pETM vector series have different tags followed
by a protease cleavage site and are based on the same pET
backbone [8]. Differences in expression levels are exclu-
sively based on different tags, not on backbones differences
such as copy number, spacer sequences or others. Expres-
sion uses the powerful T7 promoter system at low vector
copy number and plasmids confer Kanamycin resistence
instead of Ampicillin, which is crucial for plasmid stability
[9], particularly in high cell density fermentations. Transi-
ent transfection of mammalian cells is another efficient and
fast method for protein production. The HEK293 (human
embryonic kidney) cell line is widely used due to high
transfection efficiency and suspension growth in serum-
free media. A variety of HEK293 cells are currently available
with significant differences in productivity [10]. The
Epstein-Barr virus nuclear antigen 1 (EBNA1) in
HEK293E cell line interacts with oriP on pTT vectors
which increases plasmid persistence and protein
expression levels [11]. Therefore we preferred to
customize pETM, pFastBac and pTT vectors for par-
allel cloning rather than adapt to a new system. The
method must be sequence and restriction-site inde-
pendent to allow for incorporation of any DNA frag-
ment into any of the vectors. It must be directional
and precise and most important, it must be fast, sim-
ple, efficient and cost-effective. SLIC cloning enables
sequence independent, precise cloning with minimal
or no changes in the amino acid sequence of the tar-
get protein and is based on homologous recombin-
ation of vector and insert with 15–25 bp homologies
on both DNA ends. The reaction is enhanced using
either T4 DNA polymerase, recA protein or incom-
plete PCR products [6]. In order to adapt vectors for
SLIC, they need to share a common stretch of
nucleotides at both ends of the linearized plasmid.
We have chosen the HRV 3C protease [12] cleavagesite and the 3’ end of the toxic ccdB gene to serve as
primer binding sites common to all of the new
vectors (Figure 1). The HRV 3C recognition site is
located downstream of the N-terminal purification or
solubility enhancing tag and can be used for tag re-
moval. The CcdB protein inhibits bacterial growth by
selective inhibition of E. coli DNA gyrase and can be
neutralized by the antitoxin ccdA. The ccdB technol-
ogy was developed by Delphi Genetics [13] and is
licenced for use in Gateway vectors as well (Life
Technologies). In the SLIC strategy presented here,
ccdB introduced into the vector series was designed
for strong constitutive expression in order to suppress
growth in non-resistant cells at 100% efficiency. The
vector is used as a PCR template for the amplification
of the linear vector fragment, where ccdB is deleted.
The ccdB gene on the template thus prevents the
carry-over of the original vector during purification
and SLIC reaction by preventing growth of colonies
not containing the gene of interest. We developed
pET, pFastBac and pTT parallel cloning vectors,
named pCoofy1-x and present protein expression data
in each of the respective host organisms.
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Vector design and cloning strategy
In order to drive strong constitutive ccdB expression from
pCoofy vectors, we used the promoter of the major outer
membrane lipoprotein OmpA, which is one of the strongest
promoters in E. coli [14]. We inserted the respective llp5
promoter variant and a Shine-Dalgarno sequence up-
stream of the ccdB coding sequence (Figure 2A) to ensure
translation. pPCRScript-LPP5-ccdB (Figure 2B) and all
pCoofy ccdB derivatives show 100% killing efficiency when
transformed into non-resistant cells. Occasionally, we
observed the occurrence of ccdB inactivation during plas-
mid propagation in ccdB Survival™ cells (Life Technolo-
gies) under high selective pressure such as plasmids with
high copy number. Therefore killing activity has to be veri-
fied for every single batch of vector DNA. However, since
we use the vectors only as templates for PCR linearization
the amount of DNA used for a single PCR is very low
and usually sufficient for multiple SLIC reactions. Typic-
ally, 1 ng plasmid DNA is needed for a single SLIC reac-
tion. We first cloned Llp5-ccdB into pETM14, pETM22,
pETM33 and pETM44 to generate pCoofy1, 2, 3 and 4
(Figure 3A and Table 1). The parallel SLIC cloningA
B
LPP5-ccdB (370 bp)








Figure 2 ccdB cassette used for pCoofy vectors. (A) The Llp5
variant of the strong E.coli major outer membrane lipoprotein
promoter was introduced upstream of the coding sequence to drive
constitutive ccdB transcription. -35 and -10 regulatory sequences are
highlighted. A Shine-Dalgarno sequence was also added to ensure
ccdB translation. The original start codon was converted to ATT (Ile,
indicated in bold) for technical reasons. (B) The ccdB cassette was
delivered by Sloning in pPCRSript (sequence available on request)
and tested for toxicity by transformation into sensitive E.coli cells.procedure was established using eGFP as gene of interest
according to the strategy illustrated in Figure 1A. pCoofy
vectors were PCR linearized with 3C - LP1 forward and
ccdB - LP2 reverse primer (Table 2). The LP1 primer
corresponds to the HRV 3C protease site , the LP2 primer
is located at the C-terminus of ccdB in order to delete the
gene upon PCR amplification. eGFP was PCR amplified
with primers composed of gene specific sequences plus
20 bp and 25 bp extensions complementary to LP1 and
LP2 vector primers, respectively (Figure 3B).
When the SLIC reaction was carried out with insert and
vector at a molar ratio of 1:3 without any treatment prior
to transformation into chemocompetent OmniMAX™
2 T1R cells, cloning efficiency was below 70%. Addition of
recA raised overall cloning efficiency to > 95%. T4 DNA
Polymerase treatment of vector and insert [6] was equally
efficient, but due to simplicity we continued with the recA
protocol. We tested several other variations to the basic
protocol, however none of these further improved cloning
efficiency: number of PCR cycles, PCR without extension
step, extended LP1 and LP2 primer length for vector and
insert PCR amplification, amount of vector and insert,
molar ratio of vector and insert, 5 min 95°C denaturation
of vector and insert mix followed by slow renaturation at
22° (data not shown). E.coli cells used for transformation
may have an impact on quantity and quality of recombin-
ation events and should be tested first. At the Max-Planck
Institute we use chemocompetent OmniMAX™ 2 T1R
cells with a typical transformation efficiency of 107/μg
pUC plasmid DNA.
Vector list and cloning statistics
The list of E.coli pCoofy vectors was extended by modify-
ing additional pETM vectors or by introducing His10,
OneStrep, S or Halo tags from templates listed in Table 1.
All N- terminal tags are followed by the HRV 3C recogni-
tion site Leu-Phe-Gln/Gly-Pro. Specific cleavage occurs
between Gln and Gly, with Gly-Pro remaining at the N
terminus of the target protein. In order to express proteins
that have to retain their native N-terminus after tag re-
moval we generated ccdB versions of pET28M-Sumo1 and
pET28M-Sumo3 vectors. The SUMO (Small Ubiquitin-
like Modifier) tag is recognized and removed by SUMO
protease in a structure specific manner to yield the target
protein with its native N terminus [15]. Cloning a target
gene into pCoofy5 and pCoofy6 requires the corre-
sponding Sumo-LP1 primer for vector and insert PCR
amplification (Table 2). We also generated E.coli vectors
with either a C-terminal His10 or OneStrep tag (Table 1),
which require the corresponding LP2 vector and insert
primer for SLIC cloning (Figure 1, Table 2). Moreover,
constructs without any N-terminal tag can be generated
using LP1 tagless primers for the appropriate backbone.
N-tagless primer were validated and used for pET and
AB
3‘CCC GGG GAC CTT GTC TTG AA 5‘ 3C primer 
5‘ATG GTG AGC AAG GGC GAG GAG CTG 3‘
ATG GTG AGC AAG GGC GAG GAG CTG TTC ... CTC GGC ATG GAC GAG CTC TAC AAG TGA
TAC CAC TCG TTC CCG CTC CTC GAC AAG ... GAG CCG TAC CTG CTC GAG ATG TTC ACT
3‘ GCT CCG TAC CTG CTC GAG ATG TTC ACT 5‘
ccdB primer  5' CCC CAG AAC ATC AGG TTA ATG GCG 3‘
LPP5-ccdB – C-tags (1350 bp) 


















Figure 3 (See legend on next page.)
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Figure 3 Representative maps of parallel ccdB vectors for protein expression in E. coli, Baculovirus and HEK293E. For each of these
hosts, one example of the pET (E. coli) (A), pFastBac (Baculovirus) (E) and pTT (HEK293E) (D) ccdB vector series is shown. All three backbones share
common LP1 (3C) and LP2 (ccdB) primer binding sites for parallel cloning. (B) Primer design is illustrated for the universal PreScission 3C-ccdB primer
pair of the pCoofy vector series. Gene specific primer sequences are fused to sequence overhangs of 20–24 nucleotides which are complementary to
the corresponding vector amplification primer (see Table 2). (C) 2nd generation ccdB cassette including C-tags The ccdB cassette as shown in
Figure 2A starting at TTGACA (−35 region) was fused to a row of C-terminal tags each separated by a stop codon. LP1 (3C) sequence was added
upstream of the ccdB coding sequence. Restriction sites at both ends were also added for subsequent cloning into different vector backbones.
The complete cassette was synthesized by GeneArt (now part of Life Technologies) with concomitant codon optimization of the tags for
eukaryotic expression.
Scholz et al. BMC Biotechnology 2013, 13:12 Page 5 of 11
http://www.biomedcentral.com/1472-6750/13/12pFastBac backbones so far (Table 2). In order to further in-
crease C-tag variations but at the same time reduce the
number of vectors to be generated we designed a 2nd gen-
eration ccdB cassette (Figure 3C). Llp5-ccdB is followed
by a row of C-terminal tags all separated by a stop codon.Table 1 Current list of pCoofys
pCoofy parental vector N-tag C
pCoofy1 pETM14 His6 n
pCoofy18 pCoofy1 His10 n
pCoofy7 pETM14 S n
pCoofy12 pCoofy1 OneStrep n
pCoofy34 pCoofy12 S-OneStrep n
pCoofy21 pCoofy12 His10-OneStrep n
pCoofy19 pCoofy1 CBP n
pCoofy2 pETM22 Trx-His6 n
pCoofy38 pCoofy2 Trx-His10 n
pCoofy3 pETM33 His6-GST n
pCoofy8 pETM14 Halo n
pCoofy35 pCoofy4 MBP n
pCoofy4 pETM44 His6-MBP n
pCoofy15 pETM14 NusA n
pCoofy16 pCoofy15 His10-NusA n
pCoofy5 pET28M-Sumo1 His6-Sumo1 n
pCoofy6 pET28M-Sumo3 His6-Sumo3 n
pCoofy17 pCoofy6 His10-Sumo3 n
pCoofy22 pCoofy7 S H
pCoofy31 pCoofy12 OneStrep H
pCoofy36 pCoofy34 S-OneStrep H
pCoofy24 pCoofy19 CBP H
pCoofy23 pCoofy14 Trx H
pCoofy25 pCoofy8 Halo H
pCoofy37 pCoofy35 MBP H
pCoofy26 pCoofy15 NusA H
pCoofy32 pCoofy1 His6 O
pCoofy33 pCoofy18 His10 O
pCoofy11 pIEX1 His10 n
pCoofy27 pFastBac His6 n
pCoofy28 pFastBac His6-GST n
pCoofy29 pFastBac His6-MBP n
pCoofy40 pTT5 none fDepending on the LP2 primer used for vector and insert
PCR linearization, either no tag, the His10, S, OneStrep,
CBP, HPC4 or Æ54CPD54 self cleaving tag is fused to the
C-terminus of the protein. Except for the Æ54CPD54 self
cleaving tag, C-terminal tags lack a protease cleavage site-tag Host fd primer rev primer
one E. coli 3C ccdB
one E. coli 3C ccdB
one E. coli 3C ccdB
one E. coli 3C ccdB
one E. coli 3C ccdB
one E. coli 3C ccdB
one E. coli 3C ccdB
one E. coli 3C ccdB
one E. coli 3C ccdB
one E. coli 3C ccdB
one E. coli 3C ccdB
one E. coli 3C ccdB
one E. coli 3C ccdB
one E. coli 3C ccdB
one E. coli 3C ccdB
one E. coli Sumo1 ccdB
one E. coli Sumo3 ccdB
one E. coli Sumo3 ccdB
is10 E. coli 3C 10His
is10 E. coli 3C 10His
is10 E. coli 3C 10His
is10 E. coli 3C 10His
is10 E. coli 3C 10His
is10 E. coli 3C 10His
is10 E. coli 3C 10His
is10 E. coli 3C 10His
neStrep E. coli 3C OneStrep
neStrep E. coli 3C OneStrep
one Insect 3C ccdB
one Insect 3C ccdB
one Insect 3C ccdB
one Insect 3C ccdB
lexible HEK293E 3C flexible
Table 2 Primer for vector amplification and
complementary primer extensions for gene of interest
LP1 forward vector primer
3C 5' GGGCCCCTGGAACAGAACTTCCAG 3'
Sumo1 5' TCCACCGGTTTGTTCCTGGTAGAC 3'







LP2 reverse vector primer
ccdB 5' CGCCATTAACCTGATGTTCTGGGG 3'
10His 5' GAGCATCATCATCATCACCAC 3'
OneStrep 5' AGCGCTTGGAGCCACCCGCAG 3'
S 5' AAAGAAACCGCTGCTGCTAAATTCG 3'
HPC4 5' GAGGACCAGGTGGACCCCCGG 3'
LP1 forward gene primer
3C 5' AAGTTCTGTTCCAGGGGCCC – GOI seq 3'
Sumo1 5' GTCTACCAGGAACAAACCGGTGGA – GOI seq 3'
Sumo3 5' GTGTTCCAGCAGCAGACCGGTGGA – GOI seq 3'
LP2 reverse gene primer
ccdB 5' CCCCAGAACATCAGGTTAATGGCG - Stop - GOI - seq 3'
10His 5' GTGGTGATGATGATGATGCTC - Stop - GOI - seq 3'
OneStrep 5' CTGCGGGTGGCTCCAAGCGCT - Stop - GOI - seq 3'
S 5' AGCAGCAGCGGTTTCTTT - Stop - GOI - seq 3'
CBP 5' CTTCCACCGCCGCTTCATC - Stop - GOI - seq 3'
HPC4 5' GGGGTCCACCTGGTCCTC – Stop - GOI - seq 3'
Æ54CPD54 5' CAGGATCTTGCCGCTGCC – Stop - GOI - seq 3'
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this ccdB - C- tag cassette into pTT5 (Figure 3D) and
validated eGFP and target gene expression in mammalian
cells. pCoofy derivatives of pFastBac1 are currently avail-
able with His6, His6GST and His6MBP N-terminal tags
(Figure 3E, Table 1).
We have effectively cloned more than 250 inserts into
all different vectors of the pCoofy series. For all constructs,
the DNA sequence of the translated gene fusion was
controlled. We did not sequence the vector backbone of
recombinant constructs, as we have never observed any
compromised vector function. Insert sizes ranged be-
tween 150 and 3939 bp, with a majority in the range of
500–1000 bp. The number of clones per SLIC reaction
varied with an average of about 20 throughout the entire
distribution of insert sizes. As we never observed any
background, we were not concerned if clone numbers
were low, as the clone was correct in almost all cases
(Figure 4).
Expression in E.coli
Prior to use for requested target proteins, every new
vector was validated with eGFP for cloning and smallscale expression in the respective host. In case the
expression level was unexpectedly low, we removed the
vector from the list. For example a His10Trx-eGFP con-
struct was expressed at about 20% of total protein in E.coli
total cell lysate. When the double tag was switched to
TrxHis10-eGFP the expression level increased to more
than 70% (data not shown). Figure 5A shows a compari-
son of expression level and solubility of eGFP fused to
several purification and solubility enhancing tags in E.
coli. Trx, MBP and NusA protein fusions show the
highest solubility as reported previously [8] and also the
highest expression level at up to 80% of total cellular
protein. Most interesting, His6GST-eGFP expressed at a
high level but at low solubility. This result corroborates
our previous observation, that His6GST expressed from
the original pETM33 vector was insoluble (data not
shown). Most of the E.coli expression data for requested
target proteins at our Protein Production Service were
collected for the first pCoofy vectors 1–4 corresponding
to N-terminal His6, His6Trx, His6GST and His6MBP
tags. In agreement with the eGFP expression data, MBP
had a major impact on protein solubility (Figure 5B).
This is also exemplified by E.coli expression of two Pil
protein mutants in pCoofy1, 2, 3, and 4 (Figure 5C): ex-
pression levels range between 50% - and 80%, of target
protein in E.coli total cell lysate with lower or no ex-
pression of the His6GST fusion protein. In the course of
the project, only the His6MBP-Pil fusion proteins were
soluble also after tag removal with HRV 3C protease
(data not shown).
Expression in insect cells
pCoofy vectors allow for parallel screening in E.coli and
insect and/or mammalian cells which has increased pro-
tein production throughput in our facilities substantially.
Here we show two examples, Vasp and ODC, where paral-
lel cloning allowed us to switch from the E.coli expression
host to the Baculovirus expression system easily without
much delay. In the case of Topoisomerase 1, Baculovirus
expression of two parallel constructs improved project
progress.
Expression of GST-Vasp in E.coli was described previ-
ously [16]. When we expressed GST-Vasp in E.coli we
observed partial proteolytical degradation and also co-
aggregation of degradation products with full-length
protein. Instead of investing time in optimizing bacterial
expression, we cloned Vasp into pFastBac derivatives
pCoofy28 (His6GST) and pCoofy29 (His6MBP) and
expressed both constructs in SF9 cells without any
signs of degradation (Figure 6A). Purified full-length
His6GST-Vasp was shown to be biologically active (data
not shown). Ornithin Decarboxylase (ODC) was prop-
erly folded when expressed in E.coli , but for co-























































Figure 4 Cloning statistic. Typically, three colonies per transformation were selected for plasmid miniprep and sequencing reaction. All of the
recombinant constructs listed here were approved to be correct by sequence alignments.
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(His6) and expressed the ODC protein in High Five cells
(Figure 6B). Again, SLIC cloning enabled rapid change
of expression host. Expression of GST-Top1 in insect
cells was described previously [17]. We cloned Top1 in
pCoofy28 (His6GST) and pCoofy29 (His6MBP) in parallel
and tested expression in High Five cells. His6MBP-Top1
showed much higher expression level than His6GST-Top1
and was purified to homogeneity in enzymatically active
form. (data not shown) (Figure 6C).
Expression in HEK293E cells
Protein purification from HEK293E cells in our hands is
not very efficient using standard immobilized metal affin-
ity purification. We therfore have introduced alternative
C-terminal purification tags into pTT5 (Figure 3C). The
ccdB - C - tag cassette into pTT5 increases plasmid size
by 1350 bp. In order to analyze if this has an impact on
transient gene expression in HEK293E cells, we compared
expression levels of both intracellular eGFP and secreted
CD40 ligand protein [18]. Both proteins were expressed
from the original pTT vectors [2] and their respective
pCoofy derivatives. Transient transfection of both genes
show comparable levels of eGFP in the total cell lysate
and CD40 ligand in the culture supernatant when either
expressed from pTT or pCoofy (Figure 7A).In order to test these alternative purification tags we
fused them to eGFP, transiently expressed in HEK293E
cells and purified with the respective affinity resin, except
Æ54CPD54, which is specifically activated by inositol
hexakisphosphate (InsP6) present in eukaryotic cells [19].
Comparison of C-terminal S-tag, His10, HPC, CBP and
OneStrep showed best expression levels for both S and
His10 tag. Protein yield was lowest for S-tag, HPC and
CBP. Best yield and purity were obtained for eGFP-One
Strep and eGFP-His10 when washed stringently with
50mM and 80mM imidazole (Figure 7B). In summary,
we have shown effective protein expression and purifi-
cation from pCoofy40 vectors that can now be included
in our parallel cloning strategy.
Conclusions
We have developed a method that allow one to tailor
any given expression vector for efficient, fast, robust and
cost-effective parallel cloning. High cloning efficiency is
guaranteed via strong constitutive ccdB expression that,
in contrast to DpnI digestion, is 100% efficient in
counterselection of parental insert-less vector. The pro-
cedure is very robust and has been easily implemented
in research groups in-house or externally. We have
generated more than 30 parallel vectors for expression
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Figure 5 Expression in E.coli. (A) eGFP was SLIC cloned into
different E.coli pCoofy vectors using standard LP1 (3C) and LP2
(ccdB) primers and expressed in BL21 Rosetta (DE3) at 24°C. 2ml
cultures were harvested and lyzed in PBS + protease inhibitors at
consistent cell density / buffer ratio. eGFP expression level in total
lysate was monitored on Agilent BioAnalyzer P80 Chips; eGFP
fluorescence in cleared lysate was recorded on a LightCyclerII
instrument. (B) Expression results for different target proteins cloned
in pCoofy1 (His6), pCoofy2 (His6Trx), pCoofy3 (His6GST) and pCoofy4
(His6MBP) plus pCoofy35 (MBP only). Proteins are classified as soluble,
insoluble or not expressed. “Soluble” proteins could be enriched by
IMAC and were further purified with or without tag. Proteins classified
as “insoluble” were not soluble in standard IMAC buffers (buffer A).
These constructs were either subject to refolding, buffer screens or
discontinued. Proteins classified as “not expressed” cover constructs,
that were expressed at low or even undetectable level in Western Blot
analysis and were thus discontinued. (C) Pil1 (UniProt: P53252). SAQ
and SFK mutants were SLIC cloned into pCoofy1 (His6), pCoofy2
(His6Trx), pCoofy3 (His6GST) and pCoofy4 (His6MBP) using standard LP1
(3C) and LP2 (ccdB) primers and expressed in BL21 Rosetta (DE3) at 30°C.
oD3 samples (0,1 ml culture of oD600 of 3 is lyzed in 50μl sample buffer)
were loaded on Agilent BioAnalyzer P80 Chips. Expression levels
indicated are based on relative peak quantification.
Mr
kDa
























Figure 6 Baculovirus expression in insect cells. pFastBac
derivatives pCoofy27 (His6), pCoofy28 (His6GST) or pCoofy29 (His6MBP)
were transformed into DH10Bac E.coli cells to generate recombinant
Baculovirus (Bac-to-BacW, Life Technologies). HighFive or SF9 cells were
either infected with P2 virus stock or Baculo Infected Insect Cells BIIC
at dilutions indicated. Cells were harvested after 72h and lyzed in SDS
Lämmli buffer. Total lysate was loaded on 4–12% NuPAGE gels (Life
Technologies). ø cells infected with non-recombinant Baculovirus.
(A) Expression of His6GST-Vasp (lanes 1 to 5) and His6MBP-Vasp
(lanes 6 to 10) (UniProt: P50552) in HighFive cells after infection
with P2 virus stock; 48 h expression , 2000 fold virus dilution (lanes
1 and 6); 72 h expression at 20.000 (lanes 2 and 7), 2000 (lanes 3
and 8), 200 (lanes 4 and 9) and 40-fold (lanes 5 and 10) virus
dilution, respectively; coomassie stained (B) Expression of His6-ODC
(NCBI RefSeq NP_002530) in HighFive cells after infection with BIIC;
lanes 1–4 BIIC at 1:500, 1:1000, 1:2000, 1:4000 dilution respectively;
coomassie stained (C) Expression of Topoisomerase I (UniProt
P04786) fused to His6GST-topisomerase I (lanes 1 to 4) and His6MBP
(lanes 5 to 7) in High Five cells. Cells were infected with BIIC at
1:500, 1:1000, 1:2000 (lanes 1 to 3 and 5 to 7), and 1:4000 (lane 4)
respectively. ø1 cells infected with insertless virus; ø2 uninfected H5
cells, ø3 uninfected SF9 cells, detected by Western Blot analysis
using His-Probe™ reagent (ThermoScientific, Braunschweig, Germany).
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consider to be helpful in our workflow. This list of
pCoofys has fundamentally increased our throughput and
success rate in protein purification. We are constantly
expanding the list of vectors and have also integrated
the ccdB-C-tag cassette into Baculovirus, Pichia pastoris
and Hansenula polymorpha vectors which still need to be
validated.
With the strategy presented here it is straightforward to
assemble any tag combination of interest for any selected
application. Moreover, with the use of SLIC, as many as
five inserts can be assembled in one reaction simultan-
eously with great efficiency [20]. Thus a modular combin-
ation of any vector element such as purification tag, signal
sequences, antibiotic resistance etc. would be possible.
The Llp-ccdB counterselection gene presented in this
work could also enhance cloning efficiency of other clon-
ing methods as RF or others.






























Figure 7 Expression in HEK293E cells. (A) pTT5-eGFP and pTT22-
CD40L (GenBank NT_039706) constructs were generated by
restriction enzyme cloning. pCoofy40L-eGFP was generated using
standard LP1 (3C) and LP2 (ccdB) primers. Coofy40-CD40L was
generated using pTT22-CD40L as template for PCR amplification of
the insert. Gene specific LP1 primer sequence included vector VEGF
signal sequence from pTT22. Recombinant plasmids were
transfected into HEK293E cells and expressed for 72h. Total lysates of
untransfected cells, pTT5-eGFP (lane 1) pCoofy40-eGFP (lane 2), cell
culture supernatants of untransfected cells, pTT5- CD40L (lane 3) and
pCoofy40-CD40L (lane 4) detected by Coomassie, silver staining and
Western Blot HisProbe™-HRP detection. (B) eGFP was SLIC cloned into
pTT derivative Coofy40 using standard LP1 (3C) primer in combination
with either His10, OneStrep, S, CBP, HPC4 LP2 primer to introduce a
C-terminal tag. Recombinant plasmids were transfected into HEK293E
cells end expressed for 72h. Total lysates of untransfected cells,
pCoofy40-eGFP fused to C-terminal S-tag (lane 1), CBP (lane 2), HPC
(lane 3), OneStrep (lane 4) and His10 (lane 5). Eluates from S-Protein
Agarose (lane 6), Calmodulin Affinity resin (lane 7), His-Select washed
with 50 column volumes (CV) 20mM imidazole buffer (lane 8), His-
Select washed with 50 CV 20mM imidazole buffer, 20 CV 50mM
imidazole buffer and 20 CV 80mM imidazole buffer (lane 9), Calmodulin
Affinity resin (lane 10, same sample as lane 7), Anti-Protein C Affinity matrix
(lane 11) and Strep-Trap™ (lane 12). Yields estimated for His10 and OneStrep
based on Bradford staining was 8 mg / L HEK culture and 3 mg /L HEK
culture respectively.
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Vector construction
Molecular biology methods were based on standard
protocols. E.coli chemocompetent ccdB survival cells and
OmniMAX™ 2 T1R cells (Life Technologies, Darmstadt,
Germany) were used for propagating ccdB plasmids and
for transforming cloning reactions, respectively. PCRprimers were ordered at Metabion (Martinsried, Germany).
PCR was performed in 50 μl reaction mixes using high
fidelity Phusion polymerase (NEB, Frankfurt, Germany).
PCR products were analyzed on agarose gels and purified
with High Pure PCR cleanup kit (Roche, Mannheim,
Germany). Plasmid DNA was prepared using NucleoBondW
or NucleoSpinW Plasmid Kits (Macherey Nagel, Düren,
Germany). pETM vectors were provided by the EMBL
[8], pTT by Yves Durocher [11] and pFastBac was
purchased at Life Technologies. Synthetic ccdB DNA
containing the promoter, Shine-Dalgarno and the coding
sequence of ccdB was synthesized by Sloning BioTechnol-
ogy (now part of Morphosys). The 2nd generation cassette
was synthesized by GeneArtW (Regensburg, Germany,
now Life Technologies).
pCoofy E.coli expression vectors were generated by
ligating the Llp5-ccdB HindIII restriction enzyme frag-
ment from pPCRSript-ccdB into HindIII linearized
pETM vectors. Additional tags, that were not present
in the EMBL vector series, were added to the list: His6
was extended to His10 with the use of primer extensions;
the OneStrep tag was PCR amplified from pPSG-IBA103-
eGFP (IBA, Göttingen, Germany), the S tag was amplified
from pET29 (Novagen, Darmstadt, Germany) and the
Halo tag was amplified from pFN18a (Promega, Mannheim,
Germany) template DNA. The pCoofy transient insect
expression vector was derived from pIEX1. Vector was
digested with XcmI and NotI and ligated to llp5-ccdB, that
was PCR linearized with XcmI / NotI primer extensions.
The pCoofy Baculovirus expression vectors were derived
from pFastBac1. The sequence spanning N tag - 3C - Llp5-
ccdB was PCR amplified using pCoofy1, pCoofy3 and
pCoofy4 as template DNA to generate pCoofy27, pCoofy28,
pCoofy29, respectively. PCR fragments were extended by
RsrII /XhoI restriction sites and ligated into pFastBac1
linearized with RsrII /XhoI. The pCoofy HEK expression
vector was derived from pTT5. The vector was linearized
with EcoRI / NotI and ligated to the ccdB - C - tag cassette,
which was PCR amplified with EcoRI / NotI primer
extensions. Prior to use, the integrity of all vectors was
verified by DNA sequencing. ccdB toxicity is a pre-
requisite for efficient counterselection and was verified for
each new vector and for each individual vector preparation
by transformation into ccdB non-resistant OmniMAX™ 2
T1R cells. Functionality in cloning and expression was
controlled for each new vector by eGFP SLIC cloning and
small scale test expression in the appropriate host.
SLIC cloning
All vectors were PCR linearized with their corresponding
LP1 and LP2 primer combination, purified and stored
at −20°C ready-to-use. Briefly, a 50 μl reaction mix
containing 25 ng vector DNA, 50 pmol of each primer
0,4mM dNTP Mix, 1 Unit Phusion Polymerase and 1x
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reaction: 1) 98°C for 3 min, 1 cycle; 2) 98°C for 30 sec
followed by 72°C for 90 sec; 30 cycles; 3) 72°C for 10
min, 1 cycle. The PCR product is purified using High
Pure PCR Cleanup Kit (Roche, Germany). The insert is
PCR linearized with primers composed of gene specific
sequences adjusted to a Tm of 56°C - 60°C plus 15 to 25
bp extensions complementary to LP1 and LP2 vector
primer. PCR conditions need to be optimized for the
respective gene. Typically 50 ng template DNA, 50 pmol
of each primer 0,4mM dNTP Mix, 1 Unit Phusion Poly-
merase and 1x Phusion Polymerase buffer was used in a
3-step PCR reaction: : 1) 96°C for 5 min, 1 cycle; 2) 96°C
for 30 sec followed by 50°C for 30 sec followed by 72°C
for about 1min/kb; 30 cycles; 3) 72°C for 10 min, 1 cycle.
The combination of LP1 and LP2 extensions has to be
appropriate for the desired vector. The main vector series
uses 3C-LP1 and ccdB-LP2. Alternative LP1 primers are
used for N-terminal Sumo1, Sumo3 or no N tag at all.
ccdB - LP2 is used in case no C-tag is introduced. It is
important to include a stop codon in the insert LP2
primer, otherwise translation will proceed two codons
(Arginine – Histidine) further downstream until the
first stop codon in the LP2 primer extension is
encountered. Diverse LP2 primers enable the introduc-
tion of certain C-terminal tags (Table 2). For expression
in HEK cells a Kozak CCACC sequence should be
added upstream the first ATG start codon in the LP1
gene specific primer sequence. A standard PCR pro-
gram over 30 cycles including the final extension step
was used. In the SLIC reaction, 100 ng of vector is
mixed with insert at a molar ratio of 1:3. 1 μl recA pro-
tein (2 μg/ml stock) plus 1 μl recA buffer (10x) (NEB,
Germany) was added to a final reaction volume of 10
μl, incubated for 30 min at 37°C and transformed into
chemocompetent OmniMAX™ 2 T1R cells with slightly
extended incubation times: 30 min on ice, 1 min heat
shock at 42°C, 5 Typically, three clones per construct
were selected and sequenced prior to use in expression.
Protein expression in E.coli
Expression plasmids were transformed into E.coli BL21
(DE3) Rosetta expression strains. Precultures were grown
overnight in yeast extract supplemented with 3,5% glycerol
(YG) at 30°C, 130 rpm. Expression cultures were either
inoculated with colonies from agar plate or with pre-
culture to a final oD600 of 0,004 and grown at 2 ml volume
in 24 deepwell plates (Whatman, GE Healthcare, Germany)
covered with airpore tape sheets (Qiagen, Hilden, Germany).
Cultures were grown in autoinduction medium [21] at
24 or 30°C for 24h or at 37°C overnight. 18°C expression
cultures in YG medium were first grown at 37°C,
induced with 0,5 – 1mM IPTG and shifted to 18°C for
over night expression. Cultures were pelleted, resuspendedin 200 μl buffer A (50 mM Na-Phosphate pH 8,0, 500 mM
NaCl, 10% glycerol, 10 mM imidazole) including protease
inhibitors AEBSF-HCl (1 mM), Aprotinin (2 μg/ml),
Leupeptin (1 μg/ml) Pepstatin (1 μg/ml) and lyzed mech-
anically in a cooled Tissue Lyzer (Retsch, Hann, Germany)
with glass beads (Sigma, Munich, Germany) at 30 Hz for 5
min. Cell extracts were centrifuged for 30 min at 14.000
rpm at 4°C.
Protein expression in insect cells
HighFive and SF9 suspension cultures were grown in
ExCell405 and ExCell420 medium, respectively (Sigma,
Munich, Germany) at 27°C in 50 mm Unitron shakers
(Infors, Bottmingen, Switzerland). 2 ml test expression
cultures were shaken in 25 ml polystyrene screw cap
tubes (Sarstedt, Nümbrecht, Germany) at 120 rpm. Cell
viability and cell size were monitored on a Vi-CELLW in-
strument (Beckman Coulter, Krefeld, Germany).
Baculovirus expression was performed according to
the Bac-to-BacW protocol (Life Technologies, Darmstadt,
Germany). Bacmid transfected SF9 cells were typically
harvested after 4–5 days, at maximum cell size and onset
of cell lysis. The titer of this first virus stock was
determined with the SF9 easy titer cell line [22]. Virus was
either amplified in 2 subsequent steps to generate P1 and
P2 virus stock or used to generate Baculo Infected Insect
Cells (BIIC) as described previously [23]. For test expres-
sion, High Five and SF9 cells were infected at 1 × 106 cells
/ ml with virus stock or BIIC at different dilutions, typic-
ally in the range of 1:1000 – 1:10.000 and harvested after
different time points. Viability and cell size was recorded
for every expression culture.
Protein expression in HEK293E cells
HEK293E suspension cells were grown in serum free Free-
style medium (Life Technologies, Darmstadt, Germany)
supplemented with G418 to 1 μg/ml and Pluronic to 0,1%
at 37°C in 50 mm Unitron CO2 (5%) shakers (Infors,
Bottmingen, Switzerland) Transient transfection was
performed as described [24]. Briefly, 10 ml suspension
cultures in 125 ml Erlenmeyer flasks were adjusted to a
cell density of 1x106 cells/ml. 1 μg plasmid DNA per ml
culture was diluted in 100 μl PBS and mixed with 2 μl
PEI (25 kDa linear, 1mg/ml, Polysciences). After 15 min
incubation at room temperature the mix was added
dropwise to the cells. For secreted proteins, A25 trypton
(OrganoTechnie, La Courneuve, France) was added to
a final concentration of 0,5% 24 h after transfection.
Cells were harvested after 72, lyzed in respective bind-
ing buffers including protease inhibitors AEBSF-HCl
(1 mM), Aprotinin (2 μg/ml), Leupeptin (1 μg/ml) Pepstatin
(1 μg/ml) and lyzed mechanically in a Dounce homogenizer.
Cell extracts were centrifuged for 30 min at 14.000 rpm
at 4°C. Depending on the C-terminal tag fused to the
Scholz et al. BMC Biotechnology 2013, 13:12 Page 11 of 11
http://www.biomedcentral.com/1472-6750/13/12protein, lysate supernatants were loaded on the following
affinity resins: His-Select (Sigma, Munich, Germany);
Calmodulin (Stratagene, Agilent Technologies, Germany),
S-Protein (Novagen, Darmstadt, Germany), Anti-Protein
C Affinity Matrix (Roche, Mannheim, Germany) and
StrepTrap™ HP (GE Healthcare, Germany). Protein bind-
ing, washing and elution was performed according to the
manufacturers instructions.
Protein detection
All proteins samples were analyzed on 4–12% SDS-PAGE
gradient gels (NuPAGE in MES buffer system, Life Tech-
nologies, Darmstadt, Germany), visualized by Coomassie
staining, Silver staining or on P80 and P230 BioAnalyzer2100
Chips (Agilent, Böblingen, Germany). For western blot
analysis, proteins were blotted on Immobilon-P PVDF
(Millipore, Schwalbach, Germany) and visualized with
HisProbe™-HRP (Thermo Scientific, Munich, Germany).
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